JP2021046422A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021046422A5 JP2021046422A5 JP2020200176A JP2020200176A JP2021046422A5 JP 2021046422 A5 JP2021046422 A5 JP 2021046422A5 JP 2020200176 A JP2020200176 A JP 2020200176A JP 2020200176 A JP2020200176 A JP 2020200176A JP 2021046422 A5 JP2021046422 A5 JP 2021046422A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- steps
- reacting
- prepared
- react
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 0 CC(*(C=C1)*=C1c1cc(N)c(C*(C[C@@]([C@](Cc2ccc(C)cc2)*(C)(C)O)OC)*(C)*)c(N)c1)N Chemical compound CC(*(C=C1)*=C1c1cc(N)c(C*(C[C@@]([C@](Cc2ccc(C)cc2)*(C)(C)O)OC)*(C)*)c(N)c1)N 0.000 description 2
- TYQRGOIPUSJXNX-ZCFIWIBFSA-N CC(C)(C)OC(N[C@@H](C(C)(C)C(F)(F)F)C(O)=O)=O Chemical compound CC(C)(C)OC(N[C@@H](C(C)(C)C(F)(F)F)C(O)=O)=O TYQRGOIPUSJXNX-ZCFIWIBFSA-N 0.000 description 1
- POSMOHKERVVHFN-SCSAIBSYSA-N CC(C)([C@@H](C(O)=O)NC(OC)=O)C(F)(F)F Chemical compound CC(C)([C@@H](C(O)=O)NC(OC)=O)C(F)(F)F POSMOHKERVVHFN-SCSAIBSYSA-N 0.000 description 1
- UAUWOBGBRCGFGR-UHFFFAOYSA-N Ic1ccc(N2CC(CC3)N(C4COC4)C3C2)nc1 Chemical compound Ic1ccc(N2CC(CC3)N(C4COC4)C3C2)nc1 UAUWOBGBRCGFGR-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762455348P | 2017-02-06 | 2017-02-06 | |
| US62/455,348 | 2017-02-06 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019542392A Division JP6814304B2 (ja) | 2017-02-06 | 2018-02-05 | Ｈｉｖ阻害剤化合物 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021016635A Division JP7282112B2 (ja) | 2017-02-06 | 2021-02-04 | Ｈｉｖ阻害剤化合物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021046422A JP2021046422A (ja) | 2021-03-25 |
| JP2021046422A5 true JP2021046422A5 (https=) | 2021-05-06 |
| JP7105853B2 JP7105853B2 (ja) | 2022-07-25 |
Family
ID=61244746
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019542392A Active JP6814304B2 (ja) | 2017-02-06 | 2018-02-05 | Ｈｉｖ阻害剤化合物 |
| JP2020200176A Active JP7105853B2 (ja) | 2017-02-06 | 2020-12-02 | Ｈｉｖ阻害剤化合物 |
| JP2021016635A Active JP7282112B2 (ja) | 2017-02-06 | 2021-02-04 | Ｈｉｖ阻害剤化合物 |
| JP2022140748A Pending JP2022172294A (ja) | 2017-02-06 | 2022-09-05 | Ｈｉｖ阻害剤化合物 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019542392A Active JP6814304B2 (ja) | 2017-02-06 | 2018-02-05 | Ｈｉｖ阻害剤化合物 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021016635A Active JP7282112B2 (ja) | 2017-02-06 | 2021-02-04 | Ｈｉｖ阻害剤化合物 |
| JP2022140748A Pending JP2022172294A (ja) | 2017-02-06 | 2022-09-05 | Ｈｉｖ阻害剤化合物 |
Country Status (35)
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2729448B1 (en) | 2011-07-06 | 2015-09-09 | Gilead Sciences, Inc. | Compounds for the treatment of hiv |
| KR20230011471A (ko) | 2016-08-19 | 2023-01-20 | 길리애드 사이언시즈, 인코포레이티드 | Hiv 바이러스 감염의 예방적 또는 치유적 치료에 유용한 치료 화합물 |
| UY37592A (es) * | 2017-02-06 | 2018-08-31 | Gilead Sciences Inc | Compuestos inhibidores del vih |
| TWI687415B (zh) * | 2017-08-17 | 2020-03-11 | 美商基利科學股份有限公司 | Hiv蛋白質膜抑制劑之固體形式 |
| AR112412A1 (es) * | 2017-08-17 | 2019-10-23 | Gilead Sciences Inc | Formas de sal de colina de un inhibidor de la cápside del vih |
| US10836746B2 (en) | 2018-02-15 | 2020-11-17 | Gilead Sciences, Inc. | Therapeutic compounds |
| WO2019161280A1 (en) | 2018-02-16 | 2019-08-22 | Gilead Sciences, Inc. | Methods and intermediates for preparing a therapeutic compound useful in the treatment of retroviridae viral infection |
| CN120053445A (zh) | 2018-07-16 | 2025-05-30 | 吉利德科学公司 | 用于治疗hiv的衣壳抑制剂 |
| TWI829205B (zh) * | 2018-07-30 | 2024-01-11 | 美商基利科學股份有限公司 | 抗hiv化合物 |
| WO2020197991A1 (en) | 2019-03-22 | 2020-10-01 | Gilead Sciences, Inc. | Bridged tricyclic carbamoylpyridone compounds and their pharmaceutical use |
| TWI854067B (zh) | 2019-11-26 | 2024-09-01 | 美商基利科學股份有限公司 | 預防hiv之蛋白殼抑制劑 |
| US11718637B2 (en) | 2020-03-20 | 2023-08-08 | Gilead Sciences, Inc. | Prodrugs of 4′-C-substituted-2-halo-2′- deoxyadenosine nucleosides and methods of making and using the same |
| EP4153181A1 (en) | 2020-05-21 | 2023-03-29 | Gilead Sciences, Inc. | Pharmaceutical compositions comprising bictegravir |
| PL4172157T3 (pl) | 2020-06-25 | 2026-03-23 | Gilead Sciences, Inc. | Inhibitory kapsydu w leczeniu hiv |
| CA3192145A1 (en) * | 2020-09-30 | 2022-04-07 | Gilead Sciences, Inc. | Bridged tricyclic carbamoylpyridone compounds and uses thereof |
| TWI815194B (zh) | 2020-10-22 | 2023-09-11 | 美商基利科學股份有限公司 | 介白素2-Fc融合蛋白及使用方法 |
| CN116437958A (zh) | 2020-11-11 | 2023-07-14 | 吉利德科学公司 | 鉴定对采用gp120 CD4结合位点导向的抗体的疗法敏感的HIV患者的方法 |
| TW202237146A (zh) | 2021-01-25 | 2022-10-01 | 美商布里生物科學股份有限公司 | 使用腺苷衍生物及衣殼抑制劑之hiv組合療法 |
| JP7765637B2 (ja) | 2021-12-03 | 2025-11-06 | ギリアード サイエンシーズ， インコーポレイテッド | Ｈｉｖウイルス感染症のための治療化合物 |
| WO2023102523A1 (en) | 2021-12-03 | 2023-06-08 | Gilead Sciences, Inc. | Therapeutic compounds for hiv virus infection |
| DK4445900T3 (da) | 2021-12-03 | 2025-08-18 | Gilead Sciences Inc | Terapeutiske forbindelser til hiv-virusinfektion |
| TWI856796B (zh) | 2022-04-06 | 2024-09-21 | 美商基利科學股份有限公司 | 橋聯三環胺甲醯基吡啶酮化合物及其用途 |
| KR20250051732A (ko) | 2022-08-26 | 2025-04-17 | 길리애드 사이언시즈, 인코포레이티드 | 광범위 중화 항체를 위한 투여 및 일정 요법 |
| CN115215803B (zh) * | 2022-09-19 | 2022-12-30 | 苏州美诺医药科技有限公司 | 一种4-卤代-1-(二氟甲基)-1h-咪唑的制备方法 |
| EP4598934A1 (en) | 2022-10-04 | 2025-08-13 | Gilead Sciences, Inc. | 4'-thionucleoside analogues and their pharmaceutical use |
| US20240390349A1 (en) | 2023-04-19 | 2024-11-28 | Gilead Sciences, Inc. | Dosing regimen of capsid inhibitor |
| WO2024249517A1 (en) | 2023-05-31 | 2024-12-05 | Gilead Sciences, Inc. | Anti-hiv compounds |
| KR20260018877A (ko) | 2023-05-31 | 2026-02-09 | 길리애드 사이언시즈, 인코포레이티드 | Hiv 치료에 유용한 화합물의 고체 형태 |
| KR20260046169A (ko) | 2023-07-28 | 2026-04-06 | 길리애드 사이언시즈, 인코포레이티드 | Hiv의 치료 및 예방을 위한 레나카파비르 주간 투여 레지먼 |
| WO2025042394A1 (en) | 2023-08-23 | 2025-02-27 | Gilead Sciences, Inc. | Dosing regimen of hiv capsid inhibitor |
| TW202515549A (zh) | 2023-10-11 | 2025-04-16 | 美商基利科學股份有限公司 | 橋聯三環胺甲醯基吡啶酮化合物及其用途 |
| WO2025080850A1 (en) | 2023-10-11 | 2025-04-17 | Gilead Sciences, Inc. | Bridged tricyclic carbamoylpyridone compounds and uses thereof |
| WO2025080863A1 (en) | 2023-10-11 | 2025-04-17 | Gilead Sciences, Inc. | Bridged tricyclic carbamoylpyridone compounds and uses thereof |
| US20250230163A1 (en) | 2023-12-22 | 2025-07-17 | Gilead Sciences, Inc. | Solid forms of hiv integrase inhibitors |
| WO2025184452A1 (en) | 2024-03-01 | 2025-09-04 | Gilead Sciences, Inc. | Solid forms of hiv integrase inhibitors |
| US20250296932A1 (en) | 2024-03-01 | 2025-09-25 | Gilead Sciences, Inc. | Pharmaceutical compositions comprising hiv integrase inhibitors |
| US20250326779A1 (en) | 2024-04-03 | 2025-10-23 | Gilead Sciences, Inc. | Anti-hiv compounds |
| US20260007683A1 (en) | 2024-06-14 | 2026-01-08 | Gilead Sciences, Inc. | Pharmaceutical compositions comprising hiv integrase inhibitors |
| WO2026076265A1 (en) | 2024-10-03 | 2026-04-09 | Gilead Sciences, Inc. | Combination therapy comprising bridged tricyclic carbamoylpyridone compounds and p-glycoprotein inhibitors |
Family Cites Families (88)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| DE2847064A1 (de) * | 1978-10-28 | 1980-05-08 | Boehringer Mannheim Gmbh | Verwendung von 2-cyanaziridinen als therapeutica bei strahlenschaeden |
| US4326525A (en) | 1980-10-14 | 1982-04-27 | Alza Corporation | Osmotic device that improves delivery properties of agent in situ |
| US5364620A (en) | 1983-12-22 | 1994-11-15 | Elan Corporation, Plc | Controlled absorption diltiazem formulation for once daily administration |
| US5023252A (en) | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
| US5001139A (en) | 1987-06-12 | 1991-03-19 | American Cyanamid Company | Enchancers for the transdermal flux of nivadipine |
| US4992445A (en) | 1987-06-12 | 1991-02-12 | American Cyanamid Co. | Transdermal delivery of pharmaceuticals |
| US4902514A (en) | 1988-07-21 | 1990-02-20 | Alza Corporation | Dosage form for administering nilvadipine for treating cardiovascular symptoms |
| US5753652A (en) | 1991-07-03 | 1998-05-19 | Novartis Corporation | Antiretroviral hydrazine derivatives |
| ES2093237T3 (es) | 1991-07-03 | 1996-12-16 | Ciba Geigy Ag | Derivados de hidrazina farmacologicamente activos y procedimiento para su obtencion. |
| AU2003200066B9 (en) | 1992-03-11 | 2007-02-15 | Narhex Limited | Amine Derivatives of Oxo- and Hydroxy-substituted Hydrocarbons |
| JPH07504654A (ja) | 1992-03-11 | 1995-05-25 | ナルヘックス リミテッド | オキソ及びヒドロキシ置換炭化水素のアミン誘導体 |
| WO1993022292A1 (en) | 1992-05-07 | 1993-11-11 | Merck & Co., Inc. | New quinazolines as inhibitors of hiv reverse transcriptase |
| ES2093394T3 (es) | 1992-12-23 | 1996-12-16 | Ciba Geigy Ag | Derivados de hidrazina antiretrovirales. |
| US5461067A (en) | 1993-02-25 | 1995-10-24 | Abbott Laboratories | Retroviral protease inhibiting compounds |
| DE69621651T2 (de) | 1995-11-21 | 2002-11-21 | Novartis Ag, Basel | Azahexan-derivate als substratisostere von retroviralen aspartat-proteasen |
| US5849911A (en) * | 1996-04-22 | 1998-12-15 | Novartis Finance Corporation | Antivirally active heterocyclic azahexane derivatives |
| TW409125B (en) | 1996-04-22 | 2000-10-21 | Novartis Ag | Antivirally active heterocyclic azahexane derivatives |
| WO1997046514A1 (en) | 1996-05-31 | 1997-12-11 | Novartis Ag | Process for the preparation of hydrazine derivatives useful as intermediates for the preparation of peptide analogues |
| JP4100710B2 (ja) | 1996-07-17 | 2008-06-11 | ノバルティス アクチエンゲゼルシャフト | アニリノペプチド誘導体 |
| CH694251A5 (de) | 1999-07-14 | 2004-10-15 | Eprova Ag | Herstellung von Tetrahydropterin und Derivaten. |
| EP2314563A3 (en) | 1999-12-23 | 2012-04-04 | Ampac Fine Chemicals LLC | Improved preparation of 2S,3S-N-isobutyl-N-(2-hydroxy-3-amino-4-phenylbutyl)-p-nitrobenzenesulfonylamide hydrochloride and other derivatives of 2-hydroxy-1,3-diamines |
| CA2448084A1 (en) | 2001-05-22 | 2002-11-28 | Elan Pharmaceuticals, Inc. | Aza hydroxylated ethyl amine compounds |
| MXPA03011399A (es) | 2001-06-08 | 2004-07-01 | Elan Pharm Inc | Metodos para tratar la enfermedad de alzheimer. |
| BR0212242A (pt) | 2001-08-28 | 2004-07-20 | Upjohn Co | Métodos para tratar ou previnir mal de alzheimer e uma doença, tratar mal de alzheimer e um indivìduo que tem ou para evitar que um paciente adquira uma doença ou condição, para inibir a atividade de beta-secretase, a clivagem de um isotipo de proteìna de precursor de amilóide e a produção de peptìdeo beta amilóide em uma célula e de placa beta-amilóide em um animal, para produzir um complexo beta-secretase, composição e uso de um composto |
| US7157489B2 (en) | 2002-03-12 | 2007-01-02 | The Board Of Trustees Of The University Of Illinois | HIV protease inhibitors |
| EP2359833A1 (en) | 2003-04-25 | 2011-08-24 | Gilead Sciences, Inc. | Antiviral phosphonate analogs |
| US20050131042A1 (en) | 2003-12-11 | 2005-06-16 | Flentge Charles A. | HIV protease inhibiting compounds |
| US20050131017A1 (en) | 2003-12-11 | 2005-06-16 | Degoey David A. | HIV protease inhibiting compounds |
| CA2549228C (en) | 2003-12-11 | 2013-03-19 | Abbott Laboratories | Hiv protease inhibiting compounds |
| EP1737881B1 (en) | 2004-02-27 | 2009-06-24 | Schering Corporation | Novel compounds as inhibitors of hepatitis c virus ns3 serine protease |
| CN101023090B (zh) | 2004-07-06 | 2013-03-27 | 雅培制药有限公司 | Hiv蛋白酶抑制剂的前药 |
| ME03423B (me) | 2004-07-27 | 2020-01-20 | Gilead Sciences Inc | Fosfonatni analozi jedinjenja hiv inhibitora |
| WO2006084688A1 (en) | 2005-02-10 | 2006-08-17 | Medivir Ab | HIV protease inhibitors |
| CN101309911A (zh) | 2005-06-22 | 2008-11-19 | 麻萨诸塞州大学 | Hiv-1蛋白酶抑制剂及其制备方法和使用方法 |
| GB0610242D0 (en) * | 2006-05-23 | 2006-07-05 | Novartis Ag | Organic compounds |
| JP5599611B2 (ja) * | 2006-07-21 | 2014-10-01 | ギリアード サイエンシーズ， インコーポレイテッド | 抗ウイルスプロテアーゼインヒビター |
| NZ573888A (en) | 2006-07-21 | 2012-02-24 | Gilead Sciences Inc | Aza-peptide protease inhibitors |
| JP5000704B2 (ja) | 2007-03-09 | 2012-08-15 | パイオニア株式会社 | Ａｖ編集装置、ａｖ処理装置、ａｖ編集システム、操作装置、ａｖ編集方法およびプログラム |
| CA2681718A1 (en) | 2007-03-23 | 2008-10-02 | University Of Massachusetts | Hiv-1 protease inhibitors |
| AR066972A1 (es) | 2007-06-12 | 2009-09-23 | Concert Pharmaceuticals Inc | Derivados azapeptidicos |
| US8431608B2 (en) * | 2007-08-17 | 2013-04-30 | Icagen Inc. | Heterocycles as potassium channel modulators |
| US20090076097A1 (en) | 2007-09-14 | 2009-03-19 | Protia, Llc | Deuterium-enriched atazanavir |
| MX2010005334A (es) | 2007-11-16 | 2010-05-27 | Boehringer Ingelheim Int | Inhibidores de la replicacion del virus de la inmunodeficiencia humana. |
| US9095620B2 (en) | 2008-03-12 | 2015-08-04 | Nektar Therapeutics | Reagents |
| EP2288593A1 (en) | 2008-05-08 | 2011-03-02 | Ranbaxy Laboratories Limited | Process for the preparation of 3,4-epoxy-2-amino-1-substituted butane derivatives and intermediate compounds thereof |
| TW201020245A (en) | 2008-08-20 | 2010-06-01 | Schering Corp | Ethynyl-substituted pyridine and pyrimidine derivatives and their use in treating viral infections |
| TWI466735B (zh) | 2008-09-18 | 2015-01-01 | 傑士湯淺國際股份有限公司 | 紫外線照射裝置 |
| ES2467108T3 (es) | 2008-12-09 | 2014-06-11 | Gilead Sciences, Inc. | Moduladores de receptores tipo toll |
| US20120041019A1 (en) | 2008-12-17 | 2012-02-16 | Mutz Mitchell W | Protease inhibitors |
| US8338441B2 (en) | 2009-05-15 | 2012-12-25 | Gilead Sciences, Inc. | Inhibitors of human immunodeficiency virus replication |
| WO2010132852A2 (en) | 2009-05-15 | 2010-11-18 | Amplyx Pharmaceuticals Inc. | Protease inhibitors |
| JP2012530069A (ja) | 2009-06-12 | 2012-11-29 | ネクター セラピューティックス | プロテアーゼ阻害剤、水溶性非ペプチドオリゴマーおよび親油性部分を含む共有結合体 |
| GEP20207101B (en) | 2009-07-29 | 2020-05-11 | Merck Sharp & Dohme | ENANTIO- AND STEREO-SPECIFIC SYNTHESES OF β-AMINO-α- HYDROXY AMIDES |
| EP2292589A1 (en) | 2009-09-02 | 2011-03-09 | IMTM GmbH | Novel multifunctional peptidase inhibitors, especially for medical use |
| WO2011080562A1 (en) | 2009-12-29 | 2011-07-07 | Hetero Research Foundation | Novel aza-peptides containing 2,2-disubstituted cyclobutyl and/or substituted alkoxy benzyl derivatives as antivirals |
| CN102190638A (zh) * | 2010-03-16 | 2011-09-21 | 中国科学院上海药物研究所 | 联芳基醇二胺类化合物、其药物组合物、制备方法及应用 |
| WO2011139637A1 (en) | 2010-05-03 | 2011-11-10 | Philadelphia Health & Education Corporation | Small-molecule modulators of hiv-1 capsid stability and methods thereof |
| AP2013006706A0 (en) | 2010-07-02 | 2013-02-28 | Gilead Sciences Inc | Napht-2-ylacetic acid derivatives to treat AIDS |
| KR20130124291A (ko) | 2010-07-02 | 2013-11-13 | 길리애드 사이언시즈, 인코포레이티드 | Ｈｉｖ 항바이러스 화합물로서의 2-퀴놀리닐-아세트산 유도체 |
| EP2611295B1 (en) | 2010-09-02 | 2017-07-19 | Purdue Research Foundation | Fused tricyclic ether carbamates and their use |
| US9024038B2 (en) | 2010-12-27 | 2015-05-05 | Purdue Research Foundation | Compunds and methods for treating HIV |
| WO2012092188A1 (en) | 2010-12-27 | 2012-07-05 | Ghosh Arun K | Hydrogen bond forming p1 ligands and methods for treating hiv |
| WO2012092168A1 (en) | 2010-12-27 | 2012-07-05 | Purdue Research Foundation | Fused 6,5 bicyclic ring system p2 ligands, and methods for treating hiv |
| BR112013027096A2 (pt) | 2011-04-21 | 2016-12-27 | Gilead Sciences Inc | compostos de benzotiazol e seu uso farmacêutico |
| WO2012170792A1 (en) | 2011-06-10 | 2012-12-13 | Concert Pharmaceuticals, Inc. | Atazanavir metabolite derivatives |
| EP2729448B1 (en) | 2011-07-06 | 2015-09-09 | Gilead Sciences, Inc. | Compounds for the treatment of hiv |
| CN102863512B (zh) | 2011-07-07 | 2016-04-20 | 上海泓博智源医药技术有限公司 | 抗病毒化合物 |
| GB201119401D0 (en) | 2011-11-10 | 2011-12-21 | Ucb Pharma Sa | Therapeutic agents |
| US9399645B2 (en) | 2011-12-20 | 2016-07-26 | Boehringer Ingelheim International Gmbh | Inhibitors of HIV replication |
| WO2013106781A1 (en) | 2012-01-12 | 2013-07-18 | Gan Daniel L | Eversible candle holder |
| ES2571479T3 (es) | 2012-04-20 | 2016-05-25 | Gilead Sciences Inc | Derivados del ácido benzotiazol-6-il acético y su uso para tratar una infección por VIH |
| EA030003B1 (ru) | 2012-12-21 | 2018-06-29 | Джилид Сайэнс, Инк. | Полициклическое карбамоилпиридоновое соединение и его фармацевтическое применение для лечения вич-инфекции |
| US20140221378A1 (en) | 2012-12-27 | 2014-08-07 | Japan Tobacco Inc. | SUBSTITUTED SPIROPYRIDO[1,2-a]PYRAZINE DERIVATIVE AND PHARMACEUTICAL USE OF SAME AS HIV INTEGRASE INHIBITOR |
| TW201443037A (zh) | 2013-01-09 | 2014-11-16 | Gilead Sciences Inc | 治療用化合物 |
| WO2014127052A1 (en) * | 2013-02-13 | 2014-08-21 | Zondlo Neal | Perfluoro-tert-butyl hydroxyproline |
| EP3060554A1 (en) | 2013-10-24 | 2016-08-31 | Bristol-Myers Squibb Company | Inhibitors of human immunodeficiency virus replication |
| WO2015097667A2 (en) | 2013-12-23 | 2015-07-02 | Cellworks Group, Inc., | A composition, process of preparation of said composition, kit and a method of treating cancer |
| WO2015130964A1 (en) | 2014-02-28 | 2015-09-03 | Gilead Sciences, Inc. | Therapeutic compounds |
| WO2015175704A1 (en) * | 2014-05-14 | 2015-11-19 | The Regents Of The University Of California | Inhibitors of bacterial dna gyrase with efficacy against gram-negative bacteria |
| JP6622290B2 (ja) | 2014-05-16 | 2019-12-18 | パーデュー・リサーチ・ファウンデーションＰｕｒｄｕｅ Ｒｅｓｅａｒｃｈ Ｆｏｕｎｄａｔｉｏｎ | Ｈｉｖ−１プロテアーゼ阻害剤およびその用途 |
| PT3186239T (pt) | 2014-08-29 | 2019-01-10 | Gilead Sciences Inc | Agentes antirretrovirais |
| BR112017022605A2 (pt) | 2015-04-23 | 2018-07-17 | Viiv Healthcare Uk No 5 Ltd | ?composto, composição, e, método para tratamento de infecção por hiv?. |
| BR112017024331A2 (pt) | 2015-05-15 | 2018-07-24 | Gilead Sciences, Inc. | composto, composição farmacêutica, método de tratamento de um humano, métodos para inibir a atividade de uma proteína ido1, o crescimento ou a proliferação de células cancerosas, e a imunossupressão em um paciente, e de tratamento de uma doença, e, uso de um composto |
| US10899737B2 (en) * | 2016-09-19 | 2021-01-26 | Lundbeck La Jolla Research Center, Inc. | Piperazine carbamates and methods of making and using same |
| UY37592A (es) | 2017-02-06 | 2018-08-31 | Gilead Sciences Inc | Compuestos inhibidores del vih |
| TWI829205B (zh) | 2018-07-30 | 2024-01-11 | 美商基利科學股份有限公司 | 抗hiv化合物 |
| WO2024249517A1 (en) | 2023-05-31 | 2024-12-05 | Gilead Sciences, Inc. | Anti-hiv compounds |
-
2018
- 2018-02-02 UY UY0001037592A patent/UY37592A/es not_active Application Discontinuation
- 2018-02-02 AR ARP180100247A patent/AR110922A1/es active IP Right Grant
- 2018-02-04 JO JOP/2018/0009A patent/JOP20180009A1/ar unknown
- 2018-02-05 HR HRP20210732TT patent/HRP20210732T1/hr unknown
- 2018-02-05 SI SI201830292T patent/SI3577110T1/sl unknown
- 2018-02-05 TW TW112103166A patent/TWI854464B/zh active
- 2018-02-05 SG SG11201907058TA patent/SG11201907058TA/en unknown
- 2018-02-05 WO PCT/US2018/016893 patent/WO2018145021A1/en not_active Ceased
- 2018-02-05 CR CR20190354A patent/CR20190354A/es unknown
- 2018-02-05 CN CN202210907879.2A patent/CN115093421B/zh active Active
- 2018-02-05 KR KR1020247043311A patent/KR102949652B1/ko active Active
- 2018-02-05 PL PL21165835.6T patent/PL3909949T3/pl unknown
- 2018-02-05 TW TW107103968A patent/TWI701243B/zh active
- 2018-02-05 CA CA3051588A patent/CA3051588C/en active Active
- 2018-02-05 LT LTEP21165835.6T patent/LT3909949T/lt unknown
- 2018-02-05 HU HUE18706072A patent/HUE054690T2/hu unknown
- 2018-02-05 HR HRP20251629TT patent/HRP20251629T1/hr unknown
- 2018-02-05 KR KR1020227027022A patent/KR102547909B1/ko active Active
- 2018-02-05 EP EP21165835.6A patent/EP3909949B1/en active Active
- 2018-02-05 CN CN201880023198.1A patent/CN110536889B/zh active Active
- 2018-02-05 ES ES21165835T patent/ES3057738T3/es active Active
- 2018-02-05 EA EA201991684A patent/EA201991684A1/ru unknown
- 2018-02-05 PT PT211658356T patent/PT3909949T/pt unknown
- 2018-02-05 UA UAA201909440A patent/UA123298C2/uk unknown
- 2018-02-05 DK DK18706072.8T patent/DK3577110T3/da active
- 2018-02-05 MY MYPI2023007993A patent/MY207716A/en unknown
- 2018-02-05 PL PL18706072T patent/PL3577110T3/pl unknown
- 2018-02-05 TW TW109126112A patent/TWI794629B/zh active
- 2018-02-05 FI FIEP21165835.6T patent/FI3909949T3/fi active
- 2018-02-05 TW TW113128501A patent/TWI908223B/zh active
- 2018-02-05 CN CN202211475398.5A patent/CN115991708A/zh active Pending
- 2018-02-05 KR KR1020197025847A patent/KR102430812B1/ko active Active
- 2018-02-05 PE PE2019001536A patent/PE20191260A1/es unknown
- 2018-02-05 KR KR1020267010340A patent/KR20260049348A/ko active Pending
- 2018-02-05 MX MX2019009212A patent/MX2019009212A/es unknown
- 2018-02-05 ES ES18706072T patent/ES2877595T3/es active Active
- 2018-02-05 US US15/888,749 patent/US10294234B2/en active Active
- 2018-02-05 JP JP2019542392A patent/JP6814304B2/ja active Active
- 2018-02-05 LT LTEP18706072.8T patent/LT3577110T/lt unknown
- 2018-02-05 EP EP18706072.8A patent/EP3577110B1/en active Active
- 2018-02-05 KR KR1020237021040A patent/KR102749565B1/ko active Active
- 2018-02-05 MY MYPI2019004469A patent/MY200608A/en unknown
- 2018-02-05 PT PT187060728T patent/PT3577110T/pt unknown
- 2018-02-05 DK DK21165835.6T patent/DK3909949T3/da active
- 2018-02-05 SI SI201831287T patent/SI3909949T1/sl unknown
- 2018-02-05 EP EP25207785.4A patent/EP4692076A1/en active Pending
- 2018-02-05 AU AU2018215546A patent/AU2018215546B2/en active Active
-
2019
- 2019-03-26 US US16/364,487 patent/US10752636B2/en active Active
- 2019-07-25 IL IL268282A patent/IL268282B2/en unknown
- 2019-08-02 MX MX2022012616A patent/MX2022012616A/es unknown
- 2019-08-05 CL CL2019002204A patent/CL2019002204A1/es unknown
- 2019-08-05 CO CO2019008531A patent/CO2019008531A2/es unknown
- 2019-08-05 DO DO2019000201A patent/DOP2019000201A/es unknown
- 2019-08-05 PH PH12019501786A patent/PH12019501786A1/en unknown
- 2019-08-06 SA SA519402405A patent/SA519402405B1/ar unknown
-
2020
- 2020-03-02 US US16/805,933 patent/US11078208B1/en active Active
- 2020-11-04 AU AU2020264300A patent/AU2020264300B2/en active Active
- 2020-12-02 JP JP2020200176A patent/JP7105853B2/ja active Active
-
2021
- 2021-02-04 JP JP2021016635A patent/JP7282112B2/ja active Active
- 2021-04-07 US US17/224,557 patent/US12084455B2/en active Active
- 2021-06-30 CY CY20211100584T patent/CY1124276T1/el unknown
-
2022
- 2022-09-05 JP JP2022140748A patent/JP2022172294A/ja active Pending
- 2022-11-19 AU AU2022271510A patent/AU2022271510A1/en not_active Abandoned
-
2024
- 2024-06-27 US US18/756,256 patent/US12479853B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021046422A5 (https=) | ||
| US9879096B2 (en) | Process for preparation of sugammadex sodium | |
| JP2005500988A5 (https=) | ||
| JP2008524205A (ja) | アルコール溶媒中での有機フルオロ化合物の調製方法 | |
| JP2010527371A5 (https=) | ||
| US9181268B2 (en) | Anhydrate of tiotropium bromide | |
| CA2769395A1 (en) | Method for producing a radioactively marked peptide | |
| CN101918401A (zh) | 用于制备东莨菪醇酯的新方法 | |
| KR102749892B1 (ko) | 오시머티닙(azd9291) 또는 이의 염, 및 ＂azd9291 아닐린＂ 또는 이의 염의 개선된 제조 방법 | |
| WO2017037150A1 (en) | Quaternary assemblies of water-soluble non-peptide helical foldamers, their use and production thereof | |
| US20110040119A1 (en) | Method for preparing precursor of radioactive 3-iodobenzylguanidine | |
| CN111205216B (zh) | 一种制备沙格列汀的方法 | |
| JP2008544975A5 (https=) | ||
| CN101691319B (zh) | 一种合成氟代含氮杂环化合物的方法 | |
| CN101981004B (zh) | 晶体形式 | |
| US20140005355A1 (en) | Process for preparation of caspofungin acetate and intermediates | |
| JP2005510559A5 (https=) | ||
| JP2005516962A5 (https=) | ||
| JP2895959B2 (ja) | スルホニウム塩の製造方法 | |
| JP2008526698A5 (https=) | ||
| US7138523B2 (en) | Preparation of 4-(4-fluorophenyl)-N-alkylnipecotinate esters, 4-(4-fluorophenyl)-N-arylnipecotinate esters and 4-(4-fluorophenyl)-N-aralkylnipecotinate esters | |
| JPWO2022140511A5 (https=) | ||
| JP2020514373A5 (https=) | ||
| CN111247127B (zh) | 用于合成药物的中间体化合物的生产方法 | |
| JP2008524327A5 (https=) |